ANIP Valuation

ANI Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

89.710

+2.24(2.561%)1D

Overview
Forecast
Valuation
Earnings

ANIP Relative Valuation

ANIP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANIP is overvalued; if below, it's undervalued.

Historical Valuation

ANI Pharmaceuticals Inc (ANIP) is now in the Fair zone, suggesting that its current forward PE ratio of 12.24 is considered Fairly compared with the five-year average of 12.59. The fair price of ANI Pharmaceuticals Inc (ANIP) is between 70.15 to 120.35 according to relative valuation methord.

Relative Value

Fair Zone

70.15-120.35

Current Price：90.51

Fair

12.14

Trailing

Forward

9.85

EV/EBITDA

ANI Pharmaceuticals Inc. (ANIP) has a current EV/EBITDA of 9.85. The 5-year average EV/EBITDA is 9.33. The thresholds are as follows: Strongly Undervalued below 5.65, Undervalued between 5.65 and 7.49, Fairly Valued between 11.18 and 7.49, Overvalued between 11.18 and 13.02, and Strongly Overvalued above 13.02. The current Forward EV/EBITDA of 9.85 falls within the Historic Trend Line -Fairly Valued range.

42.94

EV/EBIT

ANI Pharmaceuticals Inc. (ANIP) has a current EV/EBIT of 42.94. The 5-year average EV/EBIT is 65.11. The thresholds are as follows: Strongly Undervalued below -481.15, Undervalued between -481.15 and -208.02, Fairly Valued between 338.23 and -208.02, Overvalued between 338.23 and 611.36, and Strongly Overvalued above 611.36. The current Forward EV/EBIT of 42.94 falls within the Historic Trend Line -Fairly Valued range.

2.06

ANI Pharmaceuticals Inc. (ANIP) has a current PS of 2.06. The 5-year average PS is 1.84. The thresholds are as follows: Strongly Undervalued below 1.22, Undervalued between 1.22 and 1.53, Fairly Valued between 2.15 and 1.53, Overvalued between 2.15 and 2.46, and Strongly Overvalued above 2.46. The current Forward PS of 2.06 falls within the Historic Trend Line -Fairly Valued range.

11.68

P/OCF

ANI Pharmaceuticals Inc. (ANIP) has a current P/OCF of 11.68. The 5-year average P/OCF is 12.99. The thresholds are as follows: Strongly Undervalued below -42.14, Undervalued between -42.14 and -14.58, Fairly Valued between 40.55 and -14.58, Overvalued between 40.55 and 68.11, and Strongly Overvalued above 68.11. The current Forward P/OCF of 11.68 falls within the Historic Trend Line -Fairly Valued range.

14.15

P/FCF

ANI Pharmaceuticals Inc. (ANIP) has a current P/FCF of 14.15. The 5-year average P/FCF is 11.84. The thresholds are as follows: Strongly Undervalued below -7.17, Undervalued between -7.17 and 2.33, Fairly Valued between 21.34 and 2.33, Overvalued between 21.34 and 30.84, and Strongly Overvalued above 30.84. The current Forward P/FCF of 14.15 falls within the Historic Trend Line -Fairly Valued range.

ANI Pharmaceuticals Inc (ANIP) has a current Price-to-Book (P/B) ratio of 4.03. Compared to its 3-year average P/B ratio of 2.57 , the current P/B ratio is approximately 56.72% higher. Relative to its 5-year average P/B ratio of 2.31, the current P/B ratio is about 74.34% higher. ANI Pharmaceuticals Inc (ANIP) has a Forward Free Cash Flow (FCF) yield of approximately 6.94%. Compared to its 3-year average FCF yield of 3.13%, the current FCF yield is approximately 121.64% lower. Relative to its 5-year average FCF yield of 2.41% , the current FCF yield is about 187.79% lower.

4.03

P/B

Median3y

2.57

Median5y

2.31

7.14

FCF Yield

Median3y

3.13

Median5y

2.41

Competitors Valuation Multiple

The average P/S ratio for ANIP's competitors is 364.22, providing a benchmark for relative valuation. ANI Pharmaceuticals Inc Corp (ANIP) exhibits a P/S ratio of 2.06, which is -99.43% above the industry average. Given its robust revenue growth of 53.12%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ANIP.O

ANI Pharmaceuticals Inc

Adaptive Biotechnologies Corp

Beam Therapeutics Inc

Dyne Therapeutics Inc

Loss

1.75B

Performance Decomposition

Market capitalization of ANIP increased by 40.72% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -31.27 to -134.75.

The secondary factor is the Revenue Growth, contributed 53.12%to the performance.

Overall, the performance of ANIP in the past 1 year is driven by P/E Change. Which is more unsustainable.

53.12%

138.04M → 211.37M

Revenue Growth

-343.37%

-1.66 → 4.04

Margin Expansion

330.97%

-31.27 → -134.75

P/E Change

40.72%